The outcomes of pediatric acute lymphoblastic leukemia (ALL) have improved remarkably
during the last five decades. Such improvements were made possible by the incorporation of …

The rapid development of next-generation sequencing (NGS) technology, including
advances in sequencing chemistry, sequencing technologies, bioinformatics, and data …

Myeloid neoplasms and acute leukemias derive from the clonal expansion of hematopoietic
cells driven by somatic gene mutations. Although assessment of morphology plays a crucial …

Focal radiation therapy enhances systemic responses to anti-CTLA-4 antibodies in
preclinical studies and in some patients with melanoma,–, but its efficacy in inducing …

Background Inhibition of programmed death-ligand 1 (PD-L1) with atezolizumab can induce
durable clinical benefit (DCB) in patients with metastatic urothelial cancers, including …

Early response to induction chemotherapy is an important prognostic factor in B-
lymphoblastic leukemia (B-ALL). Here, we compare high-throughput sequencing (HTS) of …

Positive detection of minimal residual disease (MRD) by multichannel flow cytometry (MFC)
prior to hematopoietic cell transplantation (HCT) of patients with acute lymphoblastic …

Abstract Background The clonoSEQ® Assay (Adaptive Biotechnologies Corporation,
Seattle, USA) identifies and tracks unique disease-associated immunoglobulin (Ig) …

As the key cellular effectors of adaptive immunity, T and B lymphocytes utilize specialized
receptors to recognize, respond to, and neutralize a diverse array of extrinsic threats. These …

Context.—A complete diagnosis of acute leukemia requires knowledge of clinical
information combined with morphologic evaluation, immunophenotyping and karyotype …